Find your next paid study

City of Hope Medical CenterNCT04930653

B-Cell Non-Hodgkin Lymphoma (NHL)Richter's TransformationT-Cell Non-Hodgkin Lymphoma+1 more

Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies

This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-C…

University of PennsylvaniaNCT07451054

Folliculotropic Mycosis FungoidesRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides+5 more

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating pat…

City of Hope Medical CenterNCT03011814

B-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic Syndrome+16 more

MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolum…

Recurrent T-Cell Non-Hodgkin LymphomaRefractory T-Cell Non-Hodgkin Lymphoma

Pralatrexate and Bendamustine With 3 Gy TBI as a New Reduced Intensity Conditioning (RIC) Regimen for Allogeneic HCT for T-Cell Lymphoma Patients Who Are in Untreated R/R, or in Remission With MRD

This phase I/II trial studies the side effects and best dose of pralatrexate in combination with bendamustine and total-body irradiation (TBI) followed by a do…

Fred Hutchinson Cancer CenterNCT07225985

Phase 2

Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have …

T-cell LymphomaGraft Versus Host DiseaseLymphoma, T-Cell+5 more

Jonathan BrammerNCT07356245

~$10 – $7,500

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications …

Recurrent Adult T-Cell Leukemia/LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/Lymphoma+1 more

A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas

This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in…